Experienced in Primitive Neuroectodermal Tumor (PNET)

Dr. Sagar D. Sardesai

Oncology
Osu Internal Medicine LLC
3900 Stoneridge Ln, 
Dublin, OH 
Accepting New Patients
Offers Telehealth
Experienced in Primitive Neuroectodermal Tumor (PNET)
Osu Internal Medicine LLC
3900 Stoneridge Ln, 
Dublin, OH 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Sagar Sardesai is an Oncologist in Dublin, Ohio. Dr. Sardesai is rated as an Experienced provider by MediFind in the treatment of Primitive Neuroectodermal Tumor (PNET). His top areas of expertise are Breast Cancer, Triple-Negative Breast Cancer, Inflammatory Breast Cancer, and Paget Disease of the Breast. Dr. Sardesai is currently accepting new patients.

His clinical research consists of co-authoring 69 peer reviewed articles and participating in 13 clinical trials. MediFind looks at clinical research from the past 15 years.

Specialties
Oncology
Licenses
Internal Medicine in OH
Hospital Affiliations
Ohio State University State Health System
Languages Spoken
English
Gender
Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Anthem
  • EPO
  • HMO
  • POS
  • PPO
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
Buckeye Health Plan
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE-MEDICAID PLAN
CareSource
  • HMO
Cigna
  • EPO
  • HMO
  • PPO
First Health
  • INSURANCE PLAN
  • MEDICARE PDP
  • PPO
Highmark
  • EPO
  • HMO
  • PPO
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Managed Medicaid
  • OTHER MANAGED MEDICAID
Medical Mutual
  • HMO
  • PPO
Oscar
  • EPO
  • HMO
  • PPO
TeamCare
  • OTHER COMMERCIAL
Trustmark
  • PPO
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 11 Less Insurance Carriers -

Locations

OSU INTERNAL MEDICINE LLC
3900 Stoneridge Ln, Dublin, OH 43017
Other Locations
OSU INTERNAL MEDICINE LLC
1145 Olentangy River Rd, Columbus, OH 43212

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

13 Clinical Trials

A Randomized, Phase III Trial to Evaluate the Efficacy and Safety of Pembrolizumab (MK-3475) as Adjuvant Therapy for Triple Receptor-Negative Breast Cancer With >/= 1 CM Residual Invasive Cancer or Positive Lymph Nodes (ypN1mi, ypN1-3) After Neoadjuvant Chemotherapy
A Randomized, Phase III Trial to Evaluate the Efficacy and Safety of Pembrolizumab (MK-3475) as Adjuvant Therapy for Triple Receptor-Negative Breast Cancer With >/= 1 CM Residual Invasive Cancer or Positive Lymph Nodes (ypN1mi, ypN1-3) After Neoadjuvant Chemotherapy
Enrollment Status: Active_not_recruiting
Publish Date: October 09, 2025
Intervention Type: Other, Radiation, Procedure, Biological
Study Drug: Pembrolizumab
Study Phase: Phase 3
A Randomized, Open Label, Phase III Trial to Evaluate the Efficacy and Safety of Palbociclib + Anti-HER2 Therapy + Endocrine Therapy vs. Anti-HER2 Therapy + Endocrine Therapy After Induction Treatment for Hormone Receptor Positive (HR+)/HER2-Positive Metastatic Breast Cancer
A Randomized, Open Label, Phase III Trial to Evaluate the Efficacy and Safety of Palbociclib + Anti-HER2 Therapy + Endocrine Therapy vs. Anti-HER2 Therapy + Endocrine Therapy After Induction Treatment for Hormone Receptor Positive (HR+)/HER2-Positive Metastatic Breast Cancer
Enrollment Status: Active_not_recruiting
Publish Date: June 11, 2025
Intervention Type: Drug
Study Drugs: Palbociclib, Trastuzumab, Pertuzumab, Letrozole, Anastrozole, Exemestane, Fulvestrant
Study Phase: Phase 3
Cool Down With EMBr: Enhancing Menopausal Hot Flash Symptom Reduction After Breast Cancer
Cool Down With EMBr: Enhancing Menopausal Hot Flash Symptom Reduction After Breast Cancer
Enrollment Status: Completed
Publish Date: April 22, 2025
Intervention Type: Device, Other
Study Phase: Not Applicable
(CompassHER2-pCR): Preoperative THP and Postoperative HP in Patients Who Achieve a Pathologic Complete Response
(CompassHER2-pCR): Preoperative THP and Postoperative HP in Patients Who Achieve a Pathologic Complete Response
Enrollment Status: Active_not_recruiting
Publish Date: April 18, 2025
Intervention Type: Procedure, Biological, Drug, Radiation
Study Drugs: Docetaxel, Nab-Paclitaxel, Paclitaxel, Pertuzumab, Trastuzumab, Trastuzumab Emtansine
Study Phase: Phase 2
A Phase 1B Clinical Trial to Evaluate the Safety and Immune Response to a Mammaglobin-A DNA Vaccine in ER+, HER2- Breast Cancer Patients Undergoing Neoadjuvant Endocrine Therapy or Chemotherapy
A Phase 1B Clinical Trial to Evaluate the Safety and Immune Response to a Mammaglobin-A DNA Vaccine in ER+, HER2- Breast Cancer Patients Undergoing Neoadjuvant Endocrine Therapy or Chemotherapy
Enrollment Status: Active_not_recruiting
Publish Date: April 17, 2025
Intervention Type: Biological, Procedure
Study Drug: Mammaglobin-A DNA Vaccine
Study Phase: Phase 1
Testing for Atypia in Random Periareolar Fine Needle Aspiration (RPFNA) Cytology After 12 Months Metformin (1, 1-Dimethylbiguanide Hydrochloride) Chemoprevention Versus Placebo Control in Premenopausal Women
Testing for Atypia in Random Periareolar Fine Needle Aspiration (RPFNA) Cytology After 12 Months Metformin (1, 1-Dimethylbiguanide Hydrochloride) Chemoprevention Versus Placebo Control in Premenopausal Women
Enrollment Status: Active_not_recruiting
Publish Date: April 13, 2025
Intervention Type: Other, Drug
Study Drug: Metformin Hydrochloride
Study Phase: Phase 3
Episodic Future Thinking: An Interventional Pilot Study to Promote Weight Loss in Breast Cancer Survivors
Episodic Future Thinking: An Interventional Pilot Study to Promote Weight Loss in Breast Cancer Survivors
Enrollment Status: Completed
Publish Date: February 07, 2025
Intervention Type: Other, Behavioral
Study Phase: Not Applicable
A Study to Assess Overall Response Rate by Inducing an Inflammatory Phenotype in Metastatic BReast cAnCEr With the Oncolytic Reovirus PeLareorEp in CombinaTion With Anti-PD-L1 Avelumab and Paclitaxel - BRACELET-1 Study
A Study to Assess Overall Response Rate by Inducing an Inflammatory Phenotype in Metastatic BReast cAnCEr With the Oncolytic Reovirus PeLareorEp in CombinaTion With Anti-PD-L1 Avelumab and Paclitaxel - BRACELET-1 Study
Enrollment Status: Active_not_recruiting
Publish Date: January 16, 2025
Intervention Type: Biological, Drug
Study Drugs: Paclitaxel, Pelareorep, Avelumab
Study Phase: Phase 2
Randomized Phase III Trial Evaluating the Role of Weight Loss in Adjuvant Treatment of Overweight and Obese Women with Early Breast Cancer
Randomized Phase III Trial Evaluating the Role of Weight Loss in Adjuvant Treatment of Overweight and Obese Women with Early Breast Cancer
Enrollment Status: Active_not_recruiting
Publish Date: January 13, 2025
Intervention Type: Other
Study Phase: Phase 3
A Phase 2 Study of Copanlisib (BAY 80-6946) in Combination With Fulvestrant in Patients With Metastatic Breast Cancer Progressing After Aromatase Inhibitor Plus CDK 4/6 Inhibitor
A Phase 2 Study of Copanlisib (BAY 80-6946) in Combination With Fulvestrant in Patients With Metastatic Breast Cancer Progressing After Aromatase Inhibitor Plus CDK 4/6 Inhibitor
Enrollment Status: Withdrawn
Publish Date: September 25, 2023
Intervention Type: Drug
Study Drugs: Copanlisib, Fulvestrant
Study Phase: Phase 1/Phase 2
Celery-Based Dietary Intervention: A Feasibility Study
Celery-Based Dietary Intervention: A Feasibility Study
Enrollment Status: Withdrawn
Publish Date: September 13, 2023
Intervention Type: Other, Procedure, Dietary supplement
Study Phase: Not Applicable
An International, Multi-Center, Open-Label, Randomized, Phase III Trial of Sacituzumab Govitecan Versus Treatment of Physician Choice in Patients With Metastatic Triple-Negative Breast Cancer Who Received at Least Two Prior Treatments
An International, Multi-Center, Open-Label, Randomized, Phase III Trial of Sacituzumab Govitecan Versus Treatment of Physician Choice in Patients With Metastatic Triple-Negative Breast Cancer Who Received at Least Two Prior Treatments
Enrollment Status: Completed
Publish Date: June 15, 2022
Intervention Type: Drug
Study Phase: Phase 3
Inhibiting Fatty Acid Synthase to Improve Efficacy of Neoadjuvant Chemotherapy
Inhibiting Fatty Acid Synthase to Improve Efficacy of Neoadjuvant Chemotherapy
Enrollment Status: Completed
Publish Date: December 15, 2021
Intervention Type: Drug
Study Drugs: chemotherapy, Omeprazole
Study Phase: Phase 2
View 12 Less Clinical Trials

69 Total Publications

Effect of Intolerance of Uncertainty on Perceived Cognitive Function Among Breast Cancer Patients Before Chemotherapy.
Effect of Intolerance of Uncertainty on Perceived Cognitive Function Among Breast Cancer Patients Before Chemotherapy.
Journal: Cancers
Published: April 17, 2025
Similar Doctors
Advanced in Primitive Neuroectodermal Tumor (PNET)
Dr. Erin R. Macrae
Oncology
Advanced in Primitive Neuroectodermal Tumor (PNET)
Dr. Erin R. Macrae
Oncology

Columbus Oncology Associates Inc

810 Jasonway Ave, Suite A, 
Columbus, OH 
 (3.9 miles away)
614-442-3130
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Erin Macrae is an Oncologist in Columbus, Ohio. Dr. Macrae is rated as a Distinguished provider by MediFind in the treatment of Primitive Neuroectodermal Tumor (PNET). Her top areas of expertise are Breast Cancer, HER-2 Positive Breast Cancer, Paget Disease of the Breast, and Familial Colorectal Cancer. Dr. Macrae is currently accepting new patients.

Distinguished in Primitive Neuroectodermal Tumor (PNET)
Dr. Erin M. Bertino
Hematology Oncology | Oncology | Hematology
Distinguished in Primitive Neuroectodermal Tumor (PNET)
Dr. Erin M. Bertino
Hematology Oncology | Oncology | Hematology

Ohiohealth Corporation

3595 Olentangy River Rd, 
Columbus, OH 
 (5.5 miles away)
614-566-5377
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Erin Bertino is a Hematologist Oncology specialist and an Oncologist in Columbus, Ohio. Dr. Bertino is rated as a Distinguished provider by MediFind in the treatment of Primitive Neuroectodermal Tumor (PNET). Her top areas of expertise are Lung Cancer, Non-Small Cell Lung Cancer (NSCLC), Small Cell Lung Cancer (SCLC), and EGFR Positive Lung Cancer. Dr. Bertino is currently accepting new patients.

Kari Kendra
Distinguished in Primitive Neuroectodermal Tumor (PNET)
Dr. Kari Kendra
Hematology | Oncology
Distinguished in Primitive Neuroectodermal Tumor (PNET)
Dr. Kari Kendra
Hematology | Oncology

Osu Internal Medicine LLC

410 W 10th Ave, 
Columbus, OH 
 (8.2 miles away)
614-293-8000
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Kari Kendra is a Hematologist and an Oncologist in Columbus, Ohio. Dr. Kendra is rated as a Distinguished provider by MediFind in the treatment of Primitive Neuroectodermal Tumor (PNET). Her top areas of expertise are Melanoma, Teratocarcinosarcoma, Olfactory Neuroblastoma, and Merkel Cell Carcinoma.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Sardesai's expertise for a condition
ConditionClose
View All 9 Experienced Conditions
Want to save this doctor for later?
Sign Up
Is this your doctor?
Find A Second Opinion
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile